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Abstract
	 Background: Chronic	 anal	 fissure	 is	 a	 common	 disease	 that	 is	 accompanied	 with	 pain	
and	 bleeding	 during	 defecation.	 Various	 surgical	 and	 non-surgical	 methods	 have	 been	 offered	
for	the	treatment	of	this	condition.	The	aim	of	this	randomised	clinical	study	was	to	compare	the	
effectiveness	and	safety	of	nifedipine	and	isosorbide	dinitrate	(ISDN)	in	the	treatment	of	chronic	
anal	fissure.	
 Methods: This	 double-blind	 clinical	 trial	 study	was	 performed	on	patients	 aged	 20	 to	 60	
years	old	in	2012	to	2013.	The	samples	with	a	primary	diagnosis	of	chronic	anal	fissure	were	enrolled	
from	the	patients	admitted	to	public	treatment	at	the	educational	Imam	Ali	Clinic,	Shahrekord,	Iran	
by	 researchers	 and	 general	 surgery	 specialists.	 The	 patients	 were	 randomised	 into	 two	 groups:	
nifedipine	0.3%	(n	=	35)	or	ISDN	0.2%	(n	=	35)	applied	three	times	a	day	for	three	weeks.	The	patients	
were	examined	on	the	7th,	14th,	and	21st	days	of	treatment,	and	the	symptoms	including	bleeding,	
pain,	and	healing	status,	as	well	as	the	side	effects	of	the	drugs,	were	assessed.	Pain	was	evaluated	
using	a	visual	analogue	scale	(VAS).
 Results:	 After	 21	 days	 of	 follow-up,	 complete	 healing	 was	 achieved	 in	 77.1%	 (n	 =	 27)	 of	
patients	in	the	nifedipine	group	and	51.4%	(n	=	18)	in	the	ISDN	group	(P =	0.05).	The	mean	VAS	of	
the	pain	on	day	21	was	0.91	(SD	0.01)	in	the	ISDN	group	and	0.45±0.78	in	the	nifedipine	group,	with	
a	statistically	 significant	difference	 (P =	0.038).	The	bleeding	was	similar	 in	 the	 two	groups	 (P	=	
0.498).
 Conclusion:	In	view	of	the	findings	on	healing	status	and	pain	in	the	patients,	nifedipine	may	
be	significantly	more	effective	in	the	treatment	of	chronic	anal	fissure	than	ISDN.
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Introduction
 Anal fissure is the most painful and common 
problem of the anorectal region. The main 
symptom of anal fissure is pain during or after 
bowel movements. The pain is usually sharp or 
cutting and intensifies during bowel movement. 
Painful bowel movements are often associated 
with bleeding. Bleeding is bright red, and the 
amount is usually insignificant and not mixed 
with the stool but is observed on toilet paper (1,2). 
Anal fissure is chronic if there is a history of anal 
pain during defecation for at least 2 months with 
sphincter fibres at the base of the lesion (3). The 
management is medical or surgical. The success 
rate of surgery is 90%, with an anal incontinence 
rate of 1–10%. Because of the complications 
of surgery, medical treatment preferred (4,5). 
Several drugs, such as glyceryl trinitrate, 
botulinum toxin, isosorbide dinitrate (ISDN), 
L-arginine, and calcium-channel blockers, have 
been used to reversibly reduce the internal 
anal sphincter tone until the fissure heals (7,8). 
Pharmacologic treatment is aimed to reduce the 
sphincter tonicity and to reversibly enhance the 
blood supply to the involved area (9). Nifedipine, 
a dihydropyridine, is a calcium antagonist that is 
currently available for oral administration for the 
42
Malays J Med Sci. Sep-Oct 2015; 22(5): 42-49
Original Article | Effects of nifedipine and isosorbide dinitrate on chronic fissure
www.mjms.usm.my 43
treatment of cardiovascular disorders and leads 
to smooth muscle relaxation and vasodilation. 
Topical nifedipine has recently been demonstrated 
to decline anal resting pressure, relieve pain, and 
heal acute anal fissures and acute thrombosed 
haemorrhoids (10,11). Similarly, topical ISDN 
has been shown to contribute to lowering the 
anal resting pressure and healing anal fissures 
(12). The success rates of topical calcium blockers 
are comparable to those of nitrates (13). The 
efficacy of topical ISDN and nifedipine for chronic 
anal fissure treatment has been previously 
demonstrated (14,15). The purpose of the present 
study is to compare the effectiveness and safety of 
nifedipine and isosorbide dinitrate in chronic anal 
fissure. The primary endpoint was fissure healing. 
Recovery of symptoms including bleeding, pain 
and the side effects of the drugs comprise the 
secondary endpoints.
Materials/Subjects and Methods
Patients and methods
 This double-blind clinical trial study was 
performed from 2012 to 2013 on patients aged 
20 to 60 years old. Subjects were enrolled 
by convenience sampling from patients with 
a primary diagnosis of chronic anal fissure 
who were admitted to public treatment at the 
educational Imam Ali Clinic, Shahrekord, Iran by 
the researcher and by a general surgery specialist. 
 In the present study, patients with more than 
a six weeks history of the disease were enrolled. 
Exclusion criteria were anal infection or cancer, 
diabetes, atopic fissure along with chronic 
intensive inflammation, immune deficiency, 
receiving oral immunosuppressive drugs or 
corticosteroids, cardiac disease and not being able 
to complete participation in the study.
Ethics
 Informed consent was obtained from all 
patients, and their data were kept confidential. 
The research protocol was approved by the Ethics 
Committee of Shahrekord University of Medical 
Sciences (ethics code: 91-8-38).
Patients’ assignment
 The patients enrolled in the study were 
randomly assigned to two groups: the first group 
received local nifedipine 0.3% ointment three 
times a day, and the second group received local 
ISDN 0.2% ointment three times a day. Patients 
in the two groups were asked to take 1–2 g of the 
ointments by the tip of the middle finger and apply 
it to the anal canal. The two groups were matched 
for age and gender. In this study, the drugs were 
encoded by an individual not included in the 
research team, and neither the researcher nor 
the patients had information about the medicine 
taken by each patient.
 The ointment was provided by a pharmacist 
in tubes with a similar shape and size. For all 
patients, a diet containing fibre and a 15 minutes 
warm bath three times a day were recommended.
Clinical follow-up
 During the initial visit, patients met with the 
general surgeon. Additionally, on the 7th, 14th, 
and 21st days after the first examination, the 
patients were assessed for symptoms including 
bleeding, pain, healing status and side effects 
due to the ointments, including severe headache, 
severe vertigo while standing, and nausea. In 
this study, the patients were followed up for a 
maximum of three weeks. 
Definition of outcome parameters
Outcome definitions
 Bleeding was classified as severe, moderate, 
mild, and no bleeding. If bleeding was consistently 
observed during bowel movements, it was classified 
as severe; if bleeding was occasionally observed 
along with bowel movements, as moderate; and if 
no blood was observed in the underwear, as mild. 
Longitudinal anal sore healing was recorded in 
terms of complete, relative and no healing (15). 
The healing was complete if the anodermal area 
was without bleeding and inflammation. Relative 
healing described decreased inflammation with 
a pale wound with or without muscle display at 
the bottom of the wound. No healing described 
a deep wound with inflamed and swollen edges 
similar to or worse than the wound at the onset 
of the treatment. Pain was assessed by a visual 
analogue scale (VAS). The patients were asked to 
score the pain prior to and after three weeks of 
treatment. In the VAS, a 10 cm long straight line, 
called a visual evaluation scale, is used for ranking 
pain intensity. On this straight line, “0” represents 
no pain and “10” represents unbearable pain. 
Effectiveness is defined as reducing bleeding and 
pain as well as increasing in patient’s healing. 
Therefore, safety is defined as no observable side 
effects resulting from the use of the drugs. At a 
power of 80% with a significance level of P < 0.05, 
and given a maximum failure rate of 10%, 36 
patients were included in each group. 
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Data analysis
 One-way repeated measures ANOVA with a 
Greenhouse Geisser correction was used to assess 
the changes in the pain score in each group. 
Student’s t test was used to test for significant 
differences in the pain score between the two 
groups at different intervals, and a chi-square test 
was used to assess the differences in bleeding, 
complications and healing status between the two 
groups. Quantitative data were used to compare 
the mean pain score between the nifedipine group 
and the ISDN group. Statistical analysis was 
conducted using SPSS 17, and a P value < 0.05 
(2-tailed) was considered significant. 
Results
 Of the 80 patients who were eligible for the 
study, 8 did not consent to participate. Of the 
remaining 72 patients, 36 were randomly assigned 
to the nifedipine group, and 36 to the ISDN 
group; however, 1 patient from the nifedipine 
group and 1 from the ISDN group were excluded 
during follow-up due to a withdrawal of consent. 
Therefore, the final analysis included 35 patients 
in the nifedipine group and 35 patients in the 
ISDN group. In the nifedipine group, there were 16 
women and 19 men; in the ISDN group, 15 women 
and 20 men. There was no significant difference 
in gender between the two groups (P = 0.81). 
The age range of the patients was 21 – 34 years 
with a mean of 33.31 (SD 6.91) in the nifedipine 
group and 25 – 44 years with mean of 34.25±5.83 
in ISDN group. Based on an independent t test, 
there was no significant difference in age between 
the two groups (P = 0.54).  
Outcomes
Bleeding
 As shown in table 1, before the treatment, 
bleeding was medium in 7 participants and mild in 
12 participants in the nifedipine group. In the ISDN 
group, bleeding was medium in 11 participants 
and mild in 14 participants. According to the chi-
square test, there was no significant difference in 
bleeding between the two groups (P = 0.474). A 
week after treatment, no bleeding was reported 
in 14 participants in the nifedipine group and in 
20 participants in the ISDN group; this difference 
Figure	1: Mean pain score, prior to and one to three weeks after treatment 
in nifedipine and isosorbide dinitrate groups. Although pain 
variation variation was not significantly different between 
the two groups (P = 0.539), the participants in both groups 
exhibited a significant relief of pain (P < 0.001).
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Table	1: Comparison of bleeding, healing status, and complications between the two groups during 
treatment intervention
P† Isosorbide	group Nifedipine	group
% No % No
One	week	after	treatment
0.017* 11.4 4 2.9 1 Severe Bleeding
14.3 5 5.7 2 Moderate
17.2 6 51.4 18 Mild
57.1 20 40 14 No 
0.320 42.9 15 31.4 11 No Healing status
57.1 20 48.6 24 Relative
0 0 0 0 Complete
0.001* 82.9 29 22.9 8 Severe headache Complications
0.150 5.7 2 0 0 Vertigo
0.001* 37.1 13 5.7 2 Nausea
Two	weeks	after	treatment
0.149 5.7 2 0 0 Severe Bleeding
11.4 4 2.9 1 Moderate
11.4 4 5.7 2 Mild
0.166 20 7 11.4 4 No Healing status
68.6 24 60 21 Relative
11.4 4 28.6 10 Complete
0.001* 42.9 15 5.7 2 Severe headache Complications
- 0 0 0 0 Vertigo
0.550 5.7 2 2.9 1 Nausea
Three	weeks	after	treatment		
0.498 0 0 0 0 Severe Bleeding
0 1 2.9 0 Moderate
2.9 2 5.7 1 Mild
0.050 14.3 5 5.7 2 No Healing status
34.3 12 17.1 6 Relative
51.4 18 77.1 27 Complete
0.150 5.7 2 0 0 Severe headache Complications
- 0 0 0 0 Vertigo
0.310 2.9 1 0 0 Nausea
*P < 0.05 significant. 
† χ2 test.
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between the groups was significant (P = 0.017). At 
two and three weeks after treatment, 91.4%  and 
97.1% in nifedipine group and 71.4%, and 91.4% 
in the ISDN group, respectively, were reported to 
have no bleeding (P = 0.149, and P = 0.498). 
Pain
 Based on table 2, before the treatment, the 
mean VAS was 7.22 in nifedipine group and 6.91 
in the ISDN group; based on an independent t 
test, there was no significant difference between 
the two groups (P = 0.162). Three weeks after 
treatment, the mean VAS was significantly less in 
the nifedipine group than in the ISDN group (P = 
0.038). The average pain scores prior to and 1– 3 
weeks after treatment are shown in figure 1.
 Based on analysis by factorial repeated 
measures ANOVA, there was no significant 
difference in pain score between the two groups 
(P = 0.539). One-way repeated measures ANOVA 
showed significant decreases in the pain score in 
the nifedipine group [F(2.012,68.4) = 883.06, P < 
0.001] as well as the ISDN group [F(1.87,63.62) = 
428.91, P < 0.001] across the four time-points.
Healing status
 Results for healing status are shown in table 
1. One week after treatment, 11 participants in 
the nifedipine group reported no healing and 
22 participants reported relative healing. In the 
ISDN group, 15 participants reported no healing 
and 20 reported relative healing (P = 0.32). At 
two and three weeks after treatment, complete 
healing was reported by less patients in the ISDN 
group than in the nifedipine group (P = 0.166 and 
P = 0.05, respectively).
Consequences of medicines
 The consequences of the medicines are 
shown in table 1. One week after treatment, eight 
participants in the nifedipine group reported 
severe headache and 2 participants reported 
nausea. In the ISDN group, 29 patients had a 
severe headache, 2 patients reported vertigo while 
standing, and 13 patients reported nausea. Severe 
headache and nausea were significantly less in 
the nifedipine group than in the ISDN group (P 
= 0.001). Two weeks after treatment, only severe 
headache was significantly less in the nifedipine 
group (P = 0.001). Three weeks after treatment, 
no consequences were reported in the nifedipine 
group, but two patients with severe headache and 
one with nausea were reported in ISDN group. 
Discussion
 Based on our findings, after 21 days of 
follow-up, of all the patients with anal fissure 
treated with ISDN and nifedipine, the nifedipine-
treated patients had significantly less VAS pain 
as compared to the ISDN-treated patients. 
Additionally, for healing status in the nifedipine 
group, the participants had complete and relative 
healing, with a significant difference from the 
ISDN group. By replicating the observations in 
each group, the pain decrease was similar, and 
after follow-up, pain was significantly relieved in 
both groups. Our study results demonstrated that 
topical nifedipine is more efficacious than ISDN. 
A numbers of studies have shown that topical 
nifedipine with a healing rate of up to 95% has a 
higher effectiveness compared to diltiazem, which 
has a 67% healing rate (16,17).
Table	2: Mean and SD of VAS of pain in the two groups during treatment intervention
P	† Three	weeks	
after	treatment
Two	weeks	
after	treatment
One	week	after	
treatment
Prior	to	
treatment
SD Mean SD Mean SD Mean SD Mean
Nifedipine	group
0.539 0.78 0.45 0.97 2 0.85 4.45 1.11 7.22 VAS of pain
Isosorbide	group
0.01 0.91 1.16 2.34 0.73 4.40 0.70 6.91 VAS of pain
0.038 * 0.185 0.765 0.162 P  ‡
*P < 0.05 significant.
† Factorial repeated-measures.
‡ t test.
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 Today, the treatment of chronic anal fissure 
has become challenging because of irreversible 
damage and deformation of the internal anal 
sphincter. Additionally, given that most patients 
with anal fissure are young and worried about non-
voluntary faeces excretion and the consequences 
after surgery, the use of alternative medicines 
for treating patients with anal fissure has been of 
recent concern (18). 
 Calcium channel blockers such as nifedipine 
have been successfully used for treating anal 
fissure (19). The transport of calcium through 
the L-type calcium channels is important for 
maintaining internal anal sphincter tone. The 
healing that results from nifedipine is due 
to not only the effect on the decrease in anal 
pressure through suppressing calcium flow into 
the sarcoplasm but also its anti-inflammatory 
effects. Studies have shown that nifedipine has an 
adjusting effect on microcirculation and a local 
anti-inflammatory effect alongside loosening of 
the internal sphincter of the anus (20). The most 
common dosage is 0.2%, which is applied topically 
2–3 times daily for 6–8 weeks. 
 In a study conducted by Golfam et al. (15), 
110 individuals were studied, out of whom 60 
were treated with nifedipine and 50 were controls 
(conventional treatment). In the nifedipine group, 
70% of patients achieved recovery, and in controls, 
12% recovery was observed after four weeks. In 
the Golfam et al. study, recovery and healing of 
the pain in the nifedipine group was significantly 
different from that of the control group.
 In the present study, severe headache 
and vomiting in occurred in 5.7% and 2.9%, 
respectively, of the patients in the ISDN group, 
while no side effects were reported in the 
nifedipine group. Thus, it can be assumed that 
nifedipine consumption is safer than ISDN. 
Headache is an important adverse event of nitrate 
treatment and occurs in up to 50% of the patients, 
who are frequently treated with simple analgesics. 
It is usually mild and leads to discontinuation of 
treatment in less than 10% of patients. A positive 
correlation between nitrate dose and headache 
has been demonstrated (6). In a study by Berkel 
et al., after nine weeks of treatment with ISDN, 
11 out of 33 patients improved, and 18 out of 27 
were treated in a Botox poison group. After one 
year of ISDN treatment, a 50% recurrence was 
observed relative to the Botox poison group (21). 
The reported success rate of ISDN is 50 – 85% 
(22–24). Regional applications of ISDN have 
reduced anal pressure, increased the anodermal 
blood flow, and made the healing of the fissure 
possible (25). However, drug doses and durations 
of treatment varied in the previously reported 
series (25–27). Kirkil  et al. (26), reported that 
treatment with 5% and 10% topical ISDN three 
times a day provided a success rate of 53.3% and 
26.7%, respectively, on the 20th day. Parellada 
(27), on the other hand, reported a success rate of 
67% with a five weeks 0.2% ISDN treatment and 
a success rate of 89% with a 10 weeks treatment, 
which is higher than the success rate of treatment 
with ISDN in the present study, probably because 
of our failure to follow the patents for a longer 
period of time. Three weeks of follow-up may be 
too early to assess the efficacy of treatment.
Many studies, including the present study, have 
shown that the first step in the treatment of 
chronic anal fissure should be medical treatment. 
In cases of lack of response to the treatment, non-
acceptance by the patient or repetitive recurrence, 
it should be treated surgically. 
 One of the strengths of the present study 
was double-blinding, which was particularly 
important, especially for pain scores, to avoid 
potential bias related to the drugs used. 
Our study does have some limitations, such as 
the small sample size of the two groups and 
failure to assess other side effects, such as blood 
pressure. In addition, follow-up of the patients 
was conducted by the same researcher who 
prescribed the treatment and hence was not blind 
to the patients’ treatment assignment. Factors 
that could potentially affect wound healing (e.g., 
smoking) were not taken into consideration. 
Despite these limitations, our study adds useful 
data regarding the treatment of anal fissure, 
though further studies are needed.
Conclusion
 In this study, nifedipine performed better 
than ISDN as a treatment for chronic anal fissures 
and was more effective for the relief of anal 
fissure pain and the healing rate. In addition, 
the relatively low occurrence of adverse effects 
presents an advantage of the nifedipine topical 
application. However, studies with larger sample 
sizes and longer follow-up (for example, 5 weeks) 
could yield findings of a higher efficacy of ISDN. 
 Further investigations with long-term follow-
up and a standard assay including evaluation 
of blood pressure and other adverse effects due 
to topical application of nifedipine and ISDN 
are needed for the precise assessment of their 
therapeutic efficacy. Therefore, studies with larger 
sample sizes might more clearly demonstrate 
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whether there are differences in adverse events 
and treatment efficacy between nifedipine and 
ISDN. 
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